Search company, investor...
Enzyme company logo


Founded Year



Seed VC | Alive

Total Raised


About Enzyme

Enzyme provides automated life science regulatory approval and compliance. The company offers quality management systems (QMS) software, consulting services, regulatory services, and more. It was founded in 2016 and is based in South San Francisco, California.

Headquarters Location

611 Gateway Boulevard Suite 120

South San Francisco, California, 94080,

United States

Missing: Enzyme's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Enzyme's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Enzyme

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Enzyme is included in 1 Expert Collection, including Regtech.



1,341 items

Technology that addresses regulatory challenges and facilitates the delivery of compliance requirements in FIs. Regulatory technology helps FIs and regulators address challenges ranging from traditional compliance and risk management to data reporting and transmission.

Enzyme Patents

Enzyme has filed 3 patents.

The 3 most popular patent topics include:

  • Amino acids
  • Computer network security
  • Disaccharides
patents chart

Application Date

Grant Date


Related Topics




Disaccharides, Sugar substitutes, Amino acids, Metabolism, Monoamine oxidase inhibitors


Application Date


Grant Date



Related Topics

Disaccharides, Sugar substitutes, Amino acids, Metabolism, Monoamine oxidase inhibitors



Latest Enzyme News wants to make FDA compliance easier for startups

Jun 13, 2021

The Food and Drug Administration approval process can be like navigating a minefield for health startups hoping to get through regulations and begin selling to the American public. YC company hopes to help these small businesses by automating the process for them. Biomedical engineer Jared Seehafer came up with the idea through his own experience consulting with health companies like Genentech. He found going through all the paperwork to get into compliance wasn’t just tedious but also a big part of what’s holding back small companies. “You find you spend almost as much time documenting the work as you do doing the work,” Seehafer told TechCrunch. “This is a multitrillion-dollar industry and I thought ‘why isn’t there software to automate the process?’ ” Compliance is the second biggest problem after raising capital for founders in the health space, according to Seehafer. So he rolled up his sleeves, brought in co-founder and regulations expert Jake Graham and launched Enzyme out of beta last summer to provide an automated software system companies can use to integrate with platforms like Jira, Trello and GitHub. Alternatives exist to help with compliance, but they often involve an expertise in the field and a hodgepodge of different software systems. With Enzyme, Seehafer says startups don’t need a background understanding in regulatory issues and don’t have to duplicate the paperwork, either. They can just plug it in and have it ready to go when the FDA comes knocking. So far Enzyme has raised $1.85 million from Refactor Capital, Data Collective, Soma Capital and Rock Health and various angels like Elizabeth Iorns from Science Exchange. The startup is currently working with about 10 companies, and Seehafer says he has an aggressive growth target for 2018, with a particular focus on targeting early funded digital health companies in need of this sort of service. He’s also going after partnerships with accelerators and VC firms to help him get in front of these companies. Of course, a company could go it on their own and try to follow guidelines placed on the FDA’s website . However, Seehafer says many end up hiring consultants, full-time compliance officers or spending exorbitant amounts of money to get them to the next phase, even with the guidelines clearly in place. “There are disincentives to making it clear [on how to get in compliance] and there’s different levels of approval for different stages,” he said. Seehafer hopes Enzyme helps founders not only navigate the process more smoothly but also educates the community so those with an idea can concentrate on innovating more and dealing with paperwork less. Would something like Enzyme have helped Theranos navigate the process? Seehafer laughed, adding the beleaguered blood testing company “didn’t follow FDA compliance 101.”

Enzyme Frequently Asked Questions (FAQ)

  • When was Enzyme founded?

    Enzyme was founded in 2016.

  • Where is Enzyme's headquarters?

    Enzyme's headquarters is located at 611 Gateway Boulevard, South San Francisco.

  • What is Enzyme's latest funding round?

    Enzyme's latest funding round is Seed VC.

  • How much did Enzyme raise?

    Enzyme raised a total of $120K.

  • Who are the investors of Enzyme?

    Investors of Enzyme include Rock Health, Y Combinator and GSR Ventures.

  • Who are Enzyme's competitors?

    Competitors of Enzyme include Domani Protocol.

Compare Enzyme to Competitors


Set delivers a portfolio management tool. It helps in bundling crypto assets together and sets crypto strategies. The company develops solutions to create cryptocurrency baskets, baskets of non-fungible tokens (NFTs), baskets of on-chain securities, and more. It offers products that include token sets, a smart contract-based asset management platform utilizing ethereum technology. It was founded in 2017 and is based in San Francisco, California.

Indexed Finance Logo
Indexed Finance

Indexed Finance provides crypto index portfolio management on Ethereum.

Enzyme Logo

Enzyme is a decentralized asset management platform that builds, scales, and monetizes an investment strategy. It provides its services to asset managers. It was founded in 2016 and is based in London, England.

Domani Protocol Logo
Domani Protocol

Domani Protocol uses decentralized traded funds to digitize asset and investment management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.